Document Detail

Targeting hematoma expansion in ICH: Illusions of hope or hope to disillusion.
MedLine Citation:
PMID:  22744666     Owner:  NLM     Status:  Publisher    
Several variables are associated with poor outcome and mortality after intracerebral hemorrhage (ICH).(1) Among modifiable factors, hematoma expansion may have a predominant role, and has been the target of recent therapeutic trials in ICH. The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT) and Antihypertensive Treatment of Acute Cerebral Hemorrhage Study (ATACH-1) showed that intensive blood pressure (BP) lowering is associated with reduced hematoma expansion during the first 24 hours of ICH(2,3); the clinical effectiveness of this strategy is undergoing evaluation in phase III trials.
Diogo C Haussen; Magdy Selim
Related Documents :
10498136 - Usefulness of tilt test-induced patterns of heart rate and blood pressure using a two-s...
2574566 - Reduced susceptibility to syncope during postural tilt in old age. is beta-blockade pro...
6496706 - Baroreflex control of plasma arginine vasopressin in humans.
11959646 - Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope.
7393156 - Noninvasive magnetic detection of cardiac mechanical activity: theory.
1780226 - Pressure management.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-27
Journal Detail:
Title:  Neurology     Volume:  -     ISSN:  1526-632X     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
Next Document:  A candidate gene for autoimmune myasthenia gravis.